Top

Published in:

01-08-2014 | Molecular Imaging

Whole-body [¹⁸F]FDG PET/MRI vs. PET/CT in the assessment of bone lesions in oncological patients: initial results

Authors: Karsten Beiderwellen, Michael Huebner, Philipp Heusch, Johannes Grueneisen, Verena Ruhlmann, Felix Nensa, Hilmar Kuehl, Lale Umutlu, Sandra Rosenbaum-Krumme, Thomas C. Lauenstein

Published in: European Radiology | Issue 8/2014

Abstract

Objectives

To compare [¹⁸ F]FDG PET/MRI with PET/CT for the assessment of bone lesions in oncologic patients.

Methods

This prospective study included 67 patients with solid tumours scheduled for PET/CT with [¹⁸ F]FDG who also underwent a whole-body PET/MRI scan. The datasets (PET/CT, PET/MRI) were rated by two readers regarding lesion conspicuity (four-point scale) and diagnostic confidence (five-point scale). Median scores were compared using the Wilcoxon test.

Results

Bone metastases were present in ten patients (15 %), and benign bone lesions in 15 patients (22 %). Bone metastases were predominantly localized in the pelvis (18 lesions, 38 %) and the spine (14 lesions, 29 %). Benign bone lesions were exclusively osteosclerotic and smaller than the metastases (mean size 6 mm vs. 23 mm). While PET/CT allowed identification of 45 of 48 bone metastases (94 %), PET/MRI allowed identification of all bone metastases (100 %). Conspicuity of metastases was high for both modalities with significantly better results using PET/MRI (p < 0.05). Diagnostic confidence in lesion detection was high for both modalities without a significant difference. In benign lesions, conspicuity and diagnostic confidence were significantly higher with PET/CT (p < 0.05).

Conclusions

[¹⁸ F]FDG PET/MRI shows high potential for the assessment of bone metastases by offering superior lesion conspicuity when compared to PET/CT. In hypersclerotic, benign bone lesions PET/CT still sets the reference.

Key Points

• PET/MRI and PET/CT are of equal value for the identification of disease-positive patients

• PET/MRI offers higher lesion conspicuity as well as diagnostic confidence

• PET/MRI is an attractive new alternative for the assessment of bone metastases

Rubens RD (1998) Bone metastases – the clinical problem. Eur J Cancer 34:210–213PubMedCrossRef

Even-Sapir E (2005) Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med 46:1356–1367PubMed

Savelli G, Maffioli L, Maccauro M, de Deckere E, Bombardieri E (2001) Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med 45:27–37PubMed

Antoch G, Vogt FM, Freudenberg LS et al (2003) Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 290:3199–3206PubMedCrossRef

Taira AV, Herfkens RJ, Gambhir SS, Quon A (2007) Detection of bone metastases: assessment of integrated FDG PET/CT imaging. Radiology 243:204–211PubMedCrossRef

Uchida K, Nakajima H, Miyazaki T et al (2013) (18)F-FDG PET/CT for diagnosis of osteosclerotic and osteolytic vertebral metastatic lesions: comparison with bone scintigraphy. Asian Spine J 7:96–103PubMedCentralPubMedCrossRef

Lauenstein TC, Freudenberg LS, Goehde SC et al (2002) Whole-body MRI using a rolling table platform for the detection of bone metastases. Eur Radiol 12:2091–2099PubMedCrossRef

Schmidt GP, Schoenberg SO, Schmid R et al (2007) Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol 17:939–949PubMedCrossRef

Iagaru A, Young P, Mittra E, Dick DW, Herfkens R, Gambhir SS (2013) Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18 F NaF PET/CT, 18 F FDG PET/CT and whole-body MRI for detection of skeletal metastases. Clin Nucl Med 38:e290–e296PubMedCrossRef

10.

Antoch G, Bockisch A (2009) Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur J Nucl Med Mol Imaging 36(Suppl 1):113–120CrossRef

11.

Martinez-Moller A, Souvatzoglou M, Delso G et al (2009) Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med 50:520–526PubMedCrossRef

12.

Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174PubMedCrossRef

13.

Drzezga A, Souvatzoglou M, Eiber M et al (2012) First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med 53:845–855PubMedCrossRef

14.

Wetter A, Lipponer C, Nensa F et al (2013) Simultaneous 18 F choline positron emission tomography/magnetic resonance imaging of the prostate: initial results. Invest Radiol 48:256–262PubMedCrossRef

15.

Beiderwellen KJ, Poeppel TD, Hartung-Knemeyer V et al (2013) Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results. Invest Radiol 48:273–279PubMedCrossRef

16.

Hartung-Knemeyer V, Rosenbaum-Krumme S, Buchbender C et al (2012) Malignant pheochromocytoma imaging with 124ImIBG PET/MR. J Clin Endocrinol Metab 97:3833–3834PubMedCrossRef

17.

Platzek I, Beuthien-Baumann B, Schneider M et al (2013) PET/MRI in head and neck cancer: initial experience. Eur J Nucl Med Mol Imaging 40:6–11PubMedCentralPubMedCrossRef

18.

Choi J, Raghavan M (2012) Diagnostic imaging and image-guided therapy of skeletal metastases. Cancer Control 19:102–112PubMed

19.

Avery R, Kuo PH (2013) 18 F sodium fluoride PET/CT detects osseous metastases from breast cancer missed on FDG PET/CT with marrow rebound. Clin Nucl Med 38:746–748PubMedCrossRef

20.

Lan X, Zhang Y, Wu Z, Jia Q, Wei H, Gao Z (2008) The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions. Clin Radiol 63:756–764PubMedCrossRef

21.

Marshall HR, Patrick J, Laidley D et al (2013) Description and assessment of a registration-based approach to include bones for attenuation correction of whole-body PET/MRI. Med Phys 40:082509PubMedCrossRef

Title: Whole-body [18F]FDG PET/MRI vs. PET/CT in the assessment of bone lesions in oncological patients: initial results
Authors: Karsten Beiderwellen
Michael Huebner
Philipp Heusch
Johannes Grueneisen
Verena Ruhlmann
Felix Nensa
Hilmar Kuehl
Lale Umutlu
Sandra Rosenbaum-Krumme
Thomas C. Lauenstein
Publication date: 01-08-2014
Publisher: Springer Berlin Heidelberg
Published in: European Radiology / Issue 8/2014
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-014-3229-3

At a glance: The STEP trials

Springer Medicine

Whole-body [¹⁸F]FDG PET/MRI vs. PET/CT in the assessment of bone lesions in oncological patients: initial results

Abstract

Objectives

Methods

Results

Conclusions

Key Points

At a glance: The STEP trials

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Key Points

Please log in to get access to this content

Other articles of this Issue 8/2014

Thermal ablation techniques: a curative treatment of bone metastases in selected patients?

MRI-based 3D pelvic autonomous innervation: a first step towards image-guided pelvic surgery

Performance of turbo high-pitch dual-source CT for coronary CT angiography: first ex vivo and patient experience

Automatic individualized contrast medium dosage during hepatic computed tomography by using computed tomography dose index volume (CTDIvol)

Iterative reconstruction technique vs filter back projection: utility for quantitative bronchial assessment on low-dose thin-section MDCT in patients with/without chronic obstructive pulmonary disease

Radiological contrast media in the breastfeeding woman: a position paper of the Italian Society of Radiology (SIRM), the Italian Society of Paediatrics (SIP), the Italian Society of Neonatology (SIN) and the Task Force on Breastfeeding, Ministry of Health, Italy